Developing Various Localized Delivery Systems
Royer Biomedical, Inc. is a privately held company based in Frederick, Maryland. Royer has a strong research background in polymer chemistry and localized therapeutic systems and holds numerous US and international patents on calcium and hydrogel matrices capable of delivering a broad array of anti-infective, anti-neoplastic, and analgesic pharmaceuticals. Royer utilizes proprietary polymer platform technologies to deliver existing pharmaceutical compounds in novel formulations. These synthetic (no animal products or collagen) proprietary platforms allow for sterile delivery, controlled elution rates, no indications of immunogenic response, and controlled rates of resorption without acid production or susceptibility to proteolytic enzyme attack.
AppliGel-gentamicin® (in clinical trial for recalcitrant skin infections) and VetriGel® wound dressing (a medical device for veterinary applications) are polymer hydrogels which can be injected and/or applied as a topical wound dressing. They form a non-abrasive flexible matrix or dressing to provide localized delivery of increased levels of pharmaceutical activity at the targeted site with decreased systemic concentrations, enhancing efficacy while reducing or eliminating systemic effects. After proof of concept, Royer intends to apply for an IND for septic arthritis and joint prophylaxis in humans. Because of AppliGel™ and VetriGel’s® unique properties and applications, Royer Biomedical has initially focused on Orthopedic, Diabetic, Anti-infective, and Oncologic applications.
Matrix III is a calcium-based matrix for depot delivery of pharmaceuticals. Matrix III Cisplatin Beads have received MUMS (Minor Use Minor Species) designation from the FDA – Center for Veterinary Medicine (CVM), and is currently undergoing clinical trial in the treatment of equine sarcoids. While undergoing formal clinical development, Matrix III cisplatin beads will be available as a compounded dosage form for veterinary use.